BS_SQX5E15Z
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 66.22864651773982
- age_years
- 11.712
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.616
- INTERFERON_ALPHA_RESPONSE+0.611
- IL6_JAK_STAT3_SIGNALING+0.561
- INFLAMMATORY_RESPONSE+0.482
- ANDROGEN_RESPONSE+0.471
- TNFA_SIGNALING_VIA_NFKB+0.463
- COMPLEMENT+0.456
- IL2_STAT5_SIGNALING+0.435
- APOPTOSIS+0.416
Top 10 suppressed
- G2M_CHECKPOINT-0.427
- E2F_TARGETS-0.376
- SPERMATOGENESIS-0.214
- HEDGEHOG_SIGNALING-0.162
- KRAS_SIGNALING_DN-0.148
- WNT_BETA_CATENIN_SIGNALING-0.126
- MITOTIC_SPINDLE-0.125
- PANCREAS_BETA_CELLS-0.111
- ESTROGEN_RESPONSE_LATE-0.009
- MYC_TARGETS_V1+0.006
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.943 |
| 2 | BS_8J3B6ZB6 | pilocytic astrocytoma | — | 0.934 |
| 3 | BS_KF0ZXDER | Meningioma | — | 0.927 |
| 4 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.926 |
| 5 | BS_E94QRJDW | low-grade glioma | — | 0.924 |
| 6 | BS_MBSTWZA6 | pilocytic astrocytoma | — | 0.918 |
| 7 | BS_DEHJF4C7 | low-grade glioma | — | 0.917 |
| 8 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.915 |
| 9 | BS_P4NX9MPA | DNET | — | 0.912 |
| 10 | BS_H3Y8FWHV | Schwannoma | — | 0.910 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.616 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.611 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.561 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.482 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.471 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.463 | Inavolisib | — uncovered |
| COMPLEMENT | 0.456 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.435 | Idelalisib | — uncovered |
| APOPTOSIS | 0.416 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.389 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.383 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.366 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.354 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.322 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.301 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.299 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.283 | Remibrutinib | — uncovered |